Ocular Therapeutix, Inc. (OCUL) Trading -3.1% Higher
Ocular Therapeutix, Inc. (NASDAQ:OCUL)’s share price traded up 3.1% during mid-day trading on Friday . The stock traded as high as $6.98 and last traded at $6.67. 245,772 shares changed hands during trading, a decline of 79% from the average session volume of 1,166,030 shares. The stock had previously closed at $6.88.
OCUL has been the topic of a number of research reports. Cantor Fitzgerald set a $35.00 price target on Ocular Therapeutix and gave the stock a “buy” rating in a report on Monday, July 10th. ValuEngine raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th. Zacks Investment Research lowered Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. BTIG Research reissued a “neutral” rating on shares of Ocular Therapeutix in a research note on Thursday, August 10th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Ocular Therapeutix currently has a consensus rating of “Hold” and a consensus price target of $22.14.
The firm’s market cap is $192.06 million. The stock has a 50-day moving average price of $6.10 and a 200 day moving average price of $8.43.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.51 million. Ocular Therapeutix had a negative return on equity of 101.03% and a negative net margin of 3,005.52%. Ocular Therapeutix’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.46) earnings per share. Equities analysts expect that Ocular Therapeutix, Inc. will post ($2.25) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in OCUL. JPMorgan Chase & Co. acquired a new position in Ocular Therapeutix in the first quarter valued at approximately $3,394,000. Wellington Management Group LLP increased its stake in Ocular Therapeutix by 35.2% in the first quarter. Wellington Management Group LLP now owns 1,312,703 shares of the biopharmaceutical company’s stock valued at $12,182,000 after purchasing an additional 341,767 shares in the last quarter. Morgan Stanley increased its stake in Ocular Therapeutix by 84.0% in the first quarter. Morgan Stanley now owns 604,636 shares of the biopharmaceutical company’s stock valued at $5,611,000 after purchasing an additional 275,950 shares in the last quarter. Vanguard Group Inc. increased its stake in Ocular Therapeutix by 24.0% in the first quarter. Vanguard Group Inc. now owns 902,262 shares of the biopharmaceutical company’s stock valued at $8,373,000 after purchasing an additional 174,688 shares in the last quarter. Finally, Cowen Inc. bought a new stake in Ocular Therapeutix in the second quarter valued at approximately $456,000. Institutional investors and hedge funds own 53.42% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/08/ocular-therapeutix-inc-ocul-trading-3-1-higher.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.